ARGX ArGEN-X SE

argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022

argenx to Report Half Year 2022 Financial Results and Second Quarter Business Update on July 28, 2022



July 21, 2022



Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, July 28, 2022 at 2:30 pm CET (8:30 am ET) to discuss its half year 2022 financial results and provide a second quarter business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of the webcast will be available on the argenx website for approximately one year following the call.

Dial-in numbers:

Use the access code 3810049 to join the call. Please dial in 15 minutes prior to the live call.

Belgium                32 800 50 201

United Kingdom        44 800 358 0970

United States                 1 888 415 4250

All other locations 1 929 526 1599

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S. and Japan. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on , , and . 

For further information, please contact:

Media:

Kelsey Kirk

Investors:

Beth DelGiacco



EN
21/07/2022

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi
ABN ABN AMRO BANK NV DEPOSITARY RECEIPTS
IBAB ION BEAM APPLICATIONS SA
CPINV CARE PROPERTY INVEST SA
ONTEX ONTEX GROUP N.V.
EXO EXOR N.V.
ARGX ARGEN-X SE
12/15/25 December 15, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx Vyvgart phase 3 in TED stopped due to lack of efficacy

argenx announced that the phase 3 (UplighTED) studies evaluating Vyvgart subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED) will be discontinued following a pre-specified unblinded interim analysis from patients completing 24 weeks of treatment. The decision to stop the trial due to lack of efficacy in TED is disappointing, however, the company notes that its pipeline strategy anticipates attrition. Of the 2026 phase 3 readouts, TED was the only program where argenx le...

12/15/25 December 15, 2025 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyr...

argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring ...

December 15, 2025 1 EN
Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Wim Lewi
SOLV SOLVAC S.A.
ARGX ARGEN-X SE
PHVS PHARVARIS NV
ENRGY ENERGYVISION
12/04/25 December 4, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
ARGX ARGEN-X SE

argenx A catalyst rich year ahead

argenx is set for a catalyst rich year ahead and has five phase 3 trial results with its lead product, Vyvgart, as well as from the next in line product empasiprubart. Those programs are supported by positive proof of concept data, and successful phase 3 results could expand the company's commercial opportunity and bring it closer to its Vision 2030 target of having 50K patients on treatment. Going into 2026, we believe continued commercial momentum and pipeline expansion potential could bring a...

12/04/25 December 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch